This page shows the details of why an item matched the keywords from your search.
| Item Type | Name |
|
Concept
|
Urinary Bladder Neoplasms
|
|
Concept
|
Urinary Bladder Diseases
|
|
Academic Article
|
Immune checkpoint inhibitors for metastatic bladder cancer.
|
|
Academic Article
|
Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate Cancer.
|
|
Academic Article
|
Mirna Expression in Bladder Cancer and Their Potential Role in Clinical Practice.
|
|
Academic Article
|
Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer.
|
|
Academic Article
|
Emerging concepts on drug resistance in bladder cancer: Implications for future strategies.
|
|
Academic Article
|
Urothelial Cancer: Inflammatory Mediators and Implications for Immunotherapy.
|
|
Academic Article
|
Re: Umberto Leone Roberti Maggiore, Simone Ferrero, Massimo Candiani, et al. Bladder Endometriosis: A Systematic Review of Pathogenesis, Diagnosis, Treatment, Impact on Fertility, and Risk of Malignant Transformation. Eur Urol 2017;71:790-807.
|
|
Academic Article
|
Metabolic phenotype of bladder cancer.
|
|
Academic Article
|
Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkers.
|
|
Academic Article
|
Bladder cancer: molecular determinants of personalized therapy.
|
|
Academic Article
|
Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?
|
|
Academic Article
|
Liquid biopsy in the clinical management of bladder cancer: current status and future developments.
|
|
Academic Article
|
Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 2 - prostate and bladder cancer.
|
|
Academic Article
|
Emerging Immunotargets in Bladder Cancer.
|
|
Academic Article
|
An Overview of Emerging Immunotargets of Genitourinary Tumors.
|
|
Academic Article
|
The route to personalized medicine in bladder cancer: where do we stand?
|
|
Academic Article
|
Prognostic Value of Beta-Tubulin-3 and c-Myc in Muscle Invasive Urothelial Carcinoma of the Bladder.
|
|
Academic Article
|
Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors.
|
|
Academic Article
|
Tp53 and its potential therapeutic role as a target in bladder cancer.
|
|
Academic Article
|
Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer.
|
|
Academic Article
|
Narrative review: update on immunotherapy and pathological features in patients with bladder cancer.
|
|
Academic Article
|
Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: a meta-analysis.
|